|
"su yy"的相關文件
顯示項目 1-50 / 68 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
| 國家衛生研究院 |
2025-09-17 |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration
|
Lin, YJ;Ou, DL;Su, YY;Hsu, CL;Hsiao, CF;Ko, BS;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Jeng, YM;Lee, WC;Chou, SC;Chen, TW;Chiu, CF;Shiuan, L, Jr.;Hsieh, CH;Lee, CC;Shen, YS;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2025-09-15 |
Effects of birth order on the prevalence of allergic diseases in Taiwanese children: A 16-year study using two national databases
|
Chan, CK;Chen, CJ;Su, YY;Chen, MH;Lin, CC;Lin, YC;Hsieh, WS;Chiou, HY;Chen, PC |
| 國家衛生研究院 |
2025-07 |
Neoadjuvant immunotherapy is associated with a recurrence free survival benefit versus active surveillance in patients with resected hepatocellular cancer
|
Brunetti, L;D'Alessio, A;Fulgenzi, CAM;Yarchoan, M;Marron, T;Blanter, J;Torkpour, A;Lombardi, P;Baretti, M;Crowley, F;Hsu, C;Cortellini, A;Su, YY;Lee, PC;Eid, JR;Kaseb, A;Pinato, DJ |
| 國家衛生研究院 |
2025-07 |
5-FU+Nal-IRI vs FOLFOX/XELOX as second-line treatment for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) after gemcitabine and nab-paclitaxel (GemNab): A propensity score-matched analysis
|
Trovato, G;Rossini, D;Su, YY;Shan, YS;Chou, WC;Bagala, C;Bensi, M;Niger, M;Marchesi, S;Garattini, SK;Michelotti, A;Chiang, NJ;Pretta, A;Scartozzi, M;Vivaldi, C;Bartalini, L;Procaccio, L;Chen, LT;Tortora, G;Salvatore, L |
| 國家衛生研究院 |
2025-04-18 |
Revisiting maternal age and child health: A nationwide birth cohort study in Taiwan
|
Su, YY;Chen, CJ;Chen, MH;Lin, CC;Hsieh, WS;Chang, H;Chan, CK;Ho, WL;Chien, MM;Chen, PC |
| 國家衛生研究院 |
2025-03 |
Single-cell RNA sequencing via endoscopic ultrasound-guided fine-needle biopsy for pancreatic tumors uncovered an aggressive subclone with a poor prognosis
|
Su, YY;Lin, MY;Cheng, SM;Chang, WL;Hsu, CW;Yeh, CM;Yu, CC;Hou, YC;Huang, CJ;Liu, YS;Chao, YJ;Wang, DY;Shan, YS;Chen, LC |
| 國家衛生研究院 |
2025-01-18 |
Intercellular TIMP-1-CD63 signaling directs the evolution of immune escape and metastasis in KRAS-mutated pancreatic cancer cells
|
Wang, CA;Hou, YC;Hong, YK;Tai, YJ;Shen, CH;Hou, PC;Fu, JL;Wu, CL;Cheng, SM;Hwang, DY;Su, YY;Shan, YS;Tsai, SJ |
| 國家衛生研究院 |
2024-11 |
Pathological response following neoadjuvant immune checkpoint inhibitors in patients with hepatocellular carcinoma: A cross-trial, patient-level analysis
|
D'Alessio, A;Stefanini, B;Blanter, J;Adegbite, B;Crowley, F;Yip, V;Slater, S;Fulgenzi, CAM;Celsa, C;Manfredi, GF;Pai, M;Goldin, RD;Ward, SC;Fiel, MI;Shu, DH;Su, YY;Cortellini, A;Baretti, M;Anders, R;Yarchoan, M;Hsu, C;Marron, TU;Pinato, DJ |
| 國家衛生研究院 |
2024-09 |
TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S-1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
|
Su, YY;Bai, LY;Huang, CJ;Chiu, CF;Wang, HT;Du, JS;Wang, HC;Chuang, S;Shih, YH;Lin, HC;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2024-08-28 |
Clinical outcomes and histologic findings of patients with hepatocellular carcinoma with durable partial response or durable stable disease after receiving atezolizumab plus bevacizumab
|
Shen, YC;Liu, TH;Nicholas, A;Soyama, A;Yuan, CT;Chen, TC;Eguchi, S;Yoshizumi, T;Itoh, S;Nakamura, N;Kosaka, H;Kaibori, M;Ishii, T;Hatano, E;Ogawa, C;Naganuma, A;Kakizaki, S;Cheng, CH;Lin, PT;Su, YY;Chuang, CH;Lu, LC;Wu, CJ;Wang, HW;Rau, KM;Hsu, CH;Lin, SM;Huang, YH;Hernandez, S;Finn, RS;Kudo, M;Cheng, AL |
| 國家衛生研究院 |
2024-08-02 |
Long-term effects on growth in preterm and small for gestational age infants: A national birth cohort study
|
Su, YY;Chen, CJ;Chen, MH;Chang, H;Chen, CM;Lin, HC;Guo, YL;Hsieh, WS;Chen, PC |
| 國家衛生研究院 |
2024-07-09 |
Cytoplasmic lipid droplets predict worse prognosis in diffuse large B-cell lymphoma: Next-generation sequencing deciphering lipogenic genes
|
Wang, SH;Chiang, PM;Su, YY;Yu, YT;Chen, YP;Chen, TY;Medeiros, LJ;Chu, CY;Chen, PC;Chang, KC |
| 國家衛生研究院 |
2024-06-21 |
A phase 1 study of biweekly nab-paclitaxel/oxaliplatin/S-1/LV for advanced upper gastrointestinal cancers: TCOG T1216 study
|
Tsai, HJ;Yang, SH;Hsiao, CF;Kao, HF;Su, YY;Shan, YS;Yen, CJ;Du, JS;Hsu, C;Wu, IC;Chen, LT |
| 國家衛生研究院 |
2024-03-25 |
Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients with metastatic pancreatic cancer
|
Tang, CY;Yang, SH;Li, CP;Su, YY;Chiu, SC;Bai, LY;Shan, YS;Chen, LT;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chiang, NJ;Chou, WC |
| 國家衛生研究院 |
2024-02-15 |
Examining arterial pulsation to identify and risk-stratify heart failure subjects with deep neural network
|
Huang, CC;Sung, SH;Wang, WT;Su, YY;Huang, CJ;Chu, TY;Chuang, SY;Chiang, CE;Chen, CH;Lin, CC;Cheng, HM |
| 國家衛生研究院 |
2024-02-15 |
Neuron-derived neurotensin promotes pancreatic cancer invasiveness and gemcitabine resistance via the NTSR1/Akt pathway
|
Hung, YH;Wang, HC;Hsu, SH;Wang, LY;Tsai, YL;Su, YY;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2024-02-13 |
Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: A multicenter study in Taiwan
|
Cheng, SM;Su, YY;Chiang, NJ;Wang, CJ;Chao, YJ;Huang, CJ;Tsai, HJ;Chen, SH;Chang, CY;Tsai, CR;Li, YJ;Yen, CJ;Chuang, SC;Chang, JSM;Shan, YS;Hwang, DY;Chen, LT |
| 國家衛生研究院 |
2024-02-01 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma- with emphasis on locoregional therapy for oligoprogression
|
Liu, TH;Chen, SC;Rau, KM;Lu, LC;Lin, PT;Su, YY;Teng, W;Lai, SW;Yeh, RH;Kao, TM;Lee, PC;Wu, CJ;Chen, CH;Hsu, CH;Lin, SM;Huang, YH;Chen, LT;Cheng, AL;Shen, YC |
| 國家衛生研究院 |
2023-Auh-15 |
Pancreatic cancer cell-derived semaphorin 3A promotes neuron recruitment to accelerate tumor growth and dissemination
|
Hung, YH;Hou, YC;Hsu, SH;Wang, LY;Tsai, YL;Shan, YS;Su, YY;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2023-12-31 |
Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation
|
Su, YY;Chiang, NJ;Chiu, TJ;Huang, CJ;Hsu, SJ;Lin, HC;Yang, SH;Yang, Y;Chou, WC;Chen, YY;Bai, LY;Li, CP;Chen, JS |
| 國家衛生研究院 |
2023-11 |
Nivolumab plus ipilimumab (N plus I) for potentially resectable hepatocellular carcinoma (HCC): Efficacy and surgical outcome
|
Su, YY;Lin, YJ;Hsiao, CF;Ou, DL;Chen, SC;Wang, HW;Wang, JH;Wu, YM;Lee, WC;Chou, SC;Ho, CL;Chiu, CF;Chen, LT;Shen, YS;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-11 |
Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
|
Su, YY;Lin, MY;Cheng, SM;Chang, WL;Yeh, CM;Yu, CC;Hsu, CW;Shan, YS;Huang, DY;Chen, LT |
| 國家衛生研究院 |
2023-06-08 |
The experience of neoadjuvant chemotherapy versus upfront surgery in resectable pancreatic cancer. a cross sectional study
|
Su, YY;Chao, YJ;Wang, CJ;Liao, TK;Su, PJ;Huang, CJ;Chiang, NJ;Yu, YT;Tsai, HM;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2023-06 |
Aristolochic acid (AA) exposure and telomere maintenance mechanism in liver angiosarcoma (AS)
|
Chen, TWW;Hsu, CL;Wu, YC;Ou, DL;Su, YY;Cheng, AL;Hsu, C |
| 國家衛生研究院 |
2023-06 |
Atezolizumab plus bevacizumab for patients with unresectable hepatocellular carcinoma and high hepatitis B viral load: Focusing on hepatic safety and viral kinetics
|
Chen, SC;Tsou, HHS;Lee, TY;Wang, HW;Chen, YH;Wang, TE;Su, YY;Yang, S;Chiu, CF;Liu, TW;Cheng, AL;Chen, LT;Hsu, C |
| 國家衛生研究院 |
2023-02-05 |
Real-world data validation of NAPOLI-1 nomogram for the prediction of overall survival in metastatic pancreatic cancer
|
Su, YY;Chiang, NJ;Yang, YH;Yen, CJ;Bai, LY;Chiu, CF;Chuang, SC;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chan, DC;Peng, CM;Chiu, SC;Li, CP;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2023-02 |
The association between UGT1A1 polymorphisms and treatment toxicities of liposomal irinotecan
|
Su, YY;Chiang, NJ;Chang, JS;Wang, YW;Shen, BN;Li, YJ;Hwang, DY;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2023-01-30 |
Investigation into the content of red material in EUS-guided pancreatic cancer biopsies
|
Lin, MY;Su, YY;Yu, YT;Huang, CJ;Sheu, BS;Chang, WL |
| 國家衛生研究院 |
2022-11-15 |
The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in patients with metastatic pancreatic ductal adenocarcinoma
|
Chiang, NJ;Shan, YS;Li, CP;Yang, SH;Su, YY;Chiu, SC;Bai, LY;Chuang, SC;Chan, DC;Yen, CJ;Peng, CM;Chiu, TJ;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2022-10 |
Outcomes of post-immunotherapy durable responders of advanced hepatocellular carcinoma - with emphasis on locoregional therapy for oligoprogression
|
Liu, TH;Chen, SC;Rau, KM;Lu, LC;Lin, PT;Su, YY;Teng, W;Lai, SW;Yehn, RH;Kao, TM;Lee, PC;Wu, CJ;Chen, CH;Hsu, CH;Lin, SM;Huang, YH;Chen, LT;Cheng, AL;Shen, YC |
| 國家衛生研究院 |
2022-09-21 |
Clustering of chromatin remodeling enzymes predicts prognosis and clinical benefit of therapeutic strategy in pancreatic cancer
|
Wang, HC;Shih, HY;Wu, CC;Chen, LT;Luo, CW;Liu, YC;Du, JS;Huang, MC;Su, YY;Chen, HD;Hsiao, HH;Moi, SH;Pan, MR |
| 國家衛生研究院 |
2022-09-02 |
Tissue quality comparison between heparinized wet suction and dry suction in endoscopic ultrasound-fine needle biopsy of solid pancreatic masses: A randomized crossover study
|
Lin, MY;Wu, CL;Su, YY;Huang, CJ;Chang, WL;Sheu, BS |
| 國家衛生研究院 |
2022-07-18 |
Impaired chromatin remodeling predicts survival to modified gemcitabine and S-1 plus nivolumab in advanced biliary tract cancer: A phase II T1219 study
|
Chiang, NJ;Tan, KT;Bai, LY;Hsiao, CF;Huang, CY;Hung, YP;Huang, CJ;Chen, SC;Shan, YS;Chao, Y;Huang, YH;Lee, IC;Lee, PC;Su, YY;Chen, SJ;Yeh, CN;Chen, LT;Chen, MH |
| 國家衛生研究院 |
2022-07 |
Improved survival with neoadjuvant chemotherapy in stage III pancreatic cancer: A single institutional experience
|
Ting, YL;Su, YY;Chiang, NJ;Chao, YJ;Li, YJ;Huang, CJ;Liao, TK;Su, PJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-07 |
Potential roles of gut microbiome in patients with hepatocellular carcinoma treated with immune checkpoint inhibitors
|
Su, YY;Lee, WH;Wang, JH;Wang, HW;Chen, TW;Chen, BB;Ho, HJ;Liu, TH;Chou, SC;Chen, BR;Liu, TW;Chen, LT;Wu, CY;Hsu, C |
| 國家衛生研究院 |
2022-07 |
A phase II trial of nivolumab, gemcitabine and S-1 as the frst-line treatment in patients with biliary tract cancer
|
Chen, MH;Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, LT |
| 國家衛生研究院 |
2022-06-22 |
Dosing pattern and early cumulative dose of liposomal irinotecan in metastatic pancreatic cancer: A real-world multicenter study
|
Su, YY;Chiang, NJ;Li, CP;Yen, CJ;Yang, SH;Chou, WC;Chen, JS;Chiu, TJ;Chen, YY;Chuang, SC;Bai, LY;Chiu, CF;Peng, CM;Chan, DC;Chiu, SC;Yang, YH;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-06-02 |
Trial Designs for integrating novel therapeutics into the management of intermediate-stage hepatocellular carcinoma
|
Su, YY;Liu, YS;Hsiao, CF;Hsu, C;Chen, LT |
| 國家衛生研究院 |
2022-05-15 |
Improved survival with induction chemotherapy and conversion surgery in locally advanced unresectable pancreatic cancer: A single institution experience
|
Su, YY;Ting, YL;Wang, CJ;Chao, YJ;Liao, TK;Su, PJ;Chiang, NJ;Liao, IC;Yu, YT;Liu, YS;Tsai, HM;Li, YJ;Huang, CJ;Liu, IT;Tsai, HJ;Yen, CJ;Shan, YS;Chen, LT |
| 國家衛生研究院 |
2022-04-15 |
The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal irinotecan
|
Yang, SH;Chiang, NJ;Chiu, SC;Chou, WC;Bai, LY;Li, CP;Su, YY;Chiu, TJ;Chuang, SC;Peng, CM;Chan, DC;Chen, JS;Yen, CJ;Chen, YY;Chiu, CF;Chen, LT;Shan, YS |
| 國家衛生研究院 |
2022-02-24 |
Semaphorin 6C suppresses proliferation of pancreatic cancer cells via inhibition of the AKT/GSK3/beta-catenin/cyclin D1 pathway
|
Hung, YH;Hsu, SH;Hou, YC;Chu, PY;Su, YY;Shan, YS;Hung, WC;Chen, LT |
| 國家衛生研究院 |
2022-02-19 |
Effect of previous conventional irinotecan treatment in patients with pancreatic cancer being treated with liposomal irinotecan plus 5-fluorouracil and leucovorin
|
Chiu, TJ;Yang, SH;Chiu, SC;Hsueh, SW;Chiang, NJ;Li, CP;Bai, LY;Cheng, FM;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Su, YY;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-12-17 |
A phase II randomised trial of induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced pancreatic cancer: the Taiwan Cooperative Oncology Group T2212 study
|
Su, YY;Chiu, YF;Li, CP;Yang, SH;Lin, J;Lin, SJ;Chang, PY;Chiang, NJ;Shan, YS;Ch’ang, HJ;Chen, LT |
| 國家衛生研究院 |
2021-11-20 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients’ experience within a population-based study
|
Chiu, TJ;Su, YY;Yang, SH;Li, CP;Bai, LY;Chiang, NJ;Chuang, SC;Shan, YS;Chan, DC;Chen, LT;Yen, CJ;Peng, CM;Chen, YY;Chen, JS;Chou, WC |
| 國家衛生研究院 |
2021-09 |
A phase II trial of nivolumab and gemcitabine and S-1 as the first-line treatment in patients with advanced biliary tract cancer
|
Chiang, NJ;Bai, LY;Huang, CJ;Chen, SC;Hsiao, CF;Shan, YS;Su, YY;Chen, L;Chen, MH |
| 國家衛生研究院 |
2021-06-15 |
Adjuvant versus neoadjuvant immunotherapy for hepatocellular carcinoma: Clinical and immunologic perspectives
|
Su, YY;Li, CC;Lin, YJ;Hsu, C |
| 中山醫學大學 |
2021 |
Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study
|
Chiu, TJ; Su, YY; Yang, SH; Li, CP; Bai, LY; Chiang, NJ; Chuang, SC; Shan, YS; Chan, DC; Chen, LT; Yen, CJ; Peng, CM; Chen, YY; Chen, JS; Chou, WC |
| 中山醫學大學 |
2021 |
Overexpression of UTX promotes tumor progression in Oral tongue squamous cell carcinoma patients receiving surgical resection: a case control study
|
Chen, YH; Chen, CH; Chien, CY; Su, YY; Luo, SD; Li, SH |
| 中山醫學大學 |
2021 |
Radiofrequency Ablation a Safe and Effective Treatment for Pediatric Benign Nodular Thyroid Goiter
|
Lin, AN; Lin, WC; Cheng, KL; Luo, SD; Chiang, PL; Chen, WC; Chen, YS; Wang, CK; Kan, NN; Su, YY |
| 國家衛生研究院 |
2020-12-29 |
Modified gemcitabine, S-1, and leucovorin combination for patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma: A multi-center retrospective study in Taiwan
|
Chen, CY;Liang, SH;Su, YY;Chiang, NJ;Wang, HC;Chiu, CF;Chen, LT;Bai, LY |
顯示項目 1-50 / 68 (共2頁)
1 2 > >>
每頁顯示[10|25|50]項目
|
